



# Klaria Interim Report Q1 2026

Klaria Interim Report Q1 2026 1 January - 31 March

## *Summary of the interim report*

First quarter of 2026 The group in total

- Net sales 0.1 MSEK (9.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for the quarter amounted to 4.9 MSEK (3.4 MSEK)
- Profit after tax amounted to -8.7 MSEK (-1.6 MSEK)
- Earnings per share for the quarter amounted to -0.04 SEK (-0.01 SEK)
- Cash flow from operating activities amounted to -0.1 MSEK (0.9 MSEK)
- Liquid assets on the balance sheet date amounted to 0.3 MSEK (1.5 MSEK)
- Group equity as of March 31 amounted to -20.6 MSEK (1.7 MSEK)
- Equity in the parent company as of March 31 amounted to 86.0 MSEK (75.4 MSEK)

**For more information, visit the Klaria Pharma Holding website [klaria.com](http://klaria.com) or contact:**

[info@klaria.com](mailto:info@klaria.com)

Tel: +46 (0) 8-446 42 99

### **This is Klaria Pharma Holding AB**

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor ([info@fnca.se](mailto:info@fnca.se), +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see [www.klaria.com](http://www.klaria.com).